Dashboard
Manage Tickers

ITCIIntra-Cellular Therapies, Inc.


$ 75.17 $ -0.15 (-0.2 %)    

Tuesday, 17-Sep-2024 15:59:43 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.83 $ -2.14 (-0.45 %)
DIA $ 417.12 $ -0.12 (-0.03 %)
SPY $ 563.14 $ 0.30 (0.05 %)
TLT $ 100.82 $ -0.51 (-0.5 %)
GLD $ 237.35 $ -1.32 (-0.55 %)
$ 75.11
$ 75.93
$ 75.08 x 100
-- x --
$ 74.68 - $ 76.49
$ 45.50 - $ 84.89
390,360
na
7.94B
$ 0.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-intra-cellular-therapies-maintains-130-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/16/2024 15:50:57

Cantor Fitzgerald analyst Charles Duncan reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and maintains $...

expert-ratings-for-intra-cellular-therapies
Expert Ratings For Intra-Cellular Therapies
09/06/2024 18:00:14

this-robinhood-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-friday
This Robinhood Analyst Is No Longer Bearis...
09/06/2024 12:59:09

piper-sandler-upgrades-intra-cellular-therapies-to-overweight-raises-price-target-to-92
Piper Sandler Upgrades Intra-Cellular Ther...
09/06/2024 12:19:29

Piper Sandler analyst Charles Duncan upgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Neutral to Overweight and raises t...

jp-morgan-maintains-overweight-on-intra-cellular-therapies-raises-price-target-to-81
JP Morgan Maintains Overweight on Intra-Ce...
08/21/2024 14:13:41

JP Morgan analyst Jessica Fye maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and raises the price target...

rbc-capital-maintains-outperform-on-intra-cellular-therapies-lowers-price-target-to-106
RBC Capital Maintains Outperform on Intra-...
08/08/2024 19:54:16

RBC Capital analyst Brian Abrahams maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and lowers the price t...

cantor-fitzgerald-maintains-overweight-on-intra-cellular-therapies-raises-price-target-to-130
Cantor Fitzgerald Maintains Overweight on ...
08/08/2024 15:23:45

Cantor Fitzgerald analyst Charles Duncan maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and raises the p...

ubs-maintains-neutral-on-intra-cellular-therapies-lowers-price-target-to-79
UBS Maintains Neutral on Intra-Cellular Th...
08/08/2024 14:22:04

UBS analyst Ashwani Verma maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and lowers the price target from $...

goldman-sachs-maintains-neutral-on-intra-cellular-therapies-lowers-price-target-to-74
Goldman Sachs Maintains Neutral on Intra-C...
08/08/2024 12:07:43

Goldman Sachs analyst Corinne Jenkins maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and lowers the price t...

needham-reiterates-buy-on-intra-cellular-therapies-maintains-100-price-target
Needham Reiterates Buy on Intra-Cellular T...
08/08/2024 11:35:06

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $100 price target.

deep-dive-into-intra-cellular-therapies-stock-analyst-perspectives-9-ratings
Deep Dive Into Intra-Cellular Therapies St...
08/07/2024 13:00:50

needham-reiterates-buy-on-intra-cellular-therapies-maintains-100-price-target
Needham Reiterates Buy on Intra-Cellular T...
08/07/2024 12:15:38

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $100 price target.

intra-cellular-therapies-announced-that-sanjeev-narula-will-join-the-company-on-august-12-2024-and-will-serve-as-executive-vice-president-chief-financial-officer
Intra-Cellular Therapies Announced That Sa...
08/07/2024 11:43:13

intra-cellular-therapies-sees-2024-caplyta-net-product-sales-650m-680m
Intra-Cellular Therapies Sees 2024 CAPLYTA...
08/07/2024 11:32:09

intra-cellular-therapies-q2-2024-gaap-eps-016-beats-020-estimate-sales-161400m-beat-157880m-estimate
Intra-Cellular Therapies Q2 2024 GAAP EPS ...
08/07/2024 11:31:41

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate...

nvidia-to-rally-around-19-here-are-10-top-analyst-forecasts-for-monday
NVIDIA To Rally Around 19%? Here Are 10 To...
07/22/2024 13:17:58

a-closer-look-at-11-analyst-recommendations-for-intra-cellular-therapies
A Closer Look at 11 Analyst Recommendation...
07/22/2024 13:00:55

needham-maintains-buy-on-intra-cellular-therapies-raises-price-target-to-100
Needham Maintains Buy on Intra-Cellular Th...
07/22/2024 09:29:14

Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $94 t...

ubs-downgrades-intra-cellular-therapies-to-neutral-lowers-price-target-to-83
UBS Downgrades Intra-Cellular Therapies to...
06/25/2024 16:16:36

UBS analyst Ashwani Verma downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral and lowers the price target ...

rbc-capital-reiterates-outperform-on-intra-cellular-therapies-maintains-103-price-target
RBC Capital Reiterates Outperform on Intra...
06/25/2024 14:10:14

RBC Capital analyst Brian Abrahams reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and maintains $103 pr...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION